Drug intelligence / Profile preview

ALM0128

Development stage: Preclinical
Lead developer: Alchemedicine
Modality: Small Molecules

Overview

ALM0128 is a preclinical-stage small molecule drug candidate developed by Alchemedicine. The program is targeted toward an undisclosed rare disease and is currently under exclusive evaluation or negotiation with an undisclosed partner. Detailed information regarding its specific molecular target and mechanism of action has not been publicly released by the developer.

Beyond the preview

Go deeper on ALM0128.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ALM0128.

Explore the full profile